ISSN: 0004-1963 eISSN: 2217-8767 Journal category: M51 Distinguished National Journal
Analysis of restricted antibiotics’ implementation in Clinical center of Montenegro during 2019. and the impact of COVID-19 epidemic on their usage
Scindeks Assistant SCIndeks Assistant
PDF

How to Cite

1.
Lukač D, Miljković B. Analysis of restricted antibiotics’ implementation in Clinical center of Montenegro during 2019. and the impact of COVID-19 epidemic on their usage. arhfarm [Internet]. 2022 Oct. 14 [cited 2026 Nov. 19];72(Suppl. 4):S292-S293. Available from: https://test.aseestant.ceon.rs/index.php/arhfarm/article/view/38050

Abstract

In 2016, Clinical center of Montenegro filed a restriction on implementation of amikacin, tobramycin, ceftazidime, cefotaxime, cefixime, cefepime, colistin, linezolid, moxifloxacin, ofloxacin, levofloxacin, meropenem, imipenem/cilastatin, ertapenem, piperacillin/tazobactam, tigecycline, vancomycin and teicoplanin. The goal of this research is analysis of restricted antibiotics’ implementation during 2019. and their usage during the COVID-19 epidemic. 174 requests for restricted antibiotics from 2019. and the usage of restricted antibiotics during the COVID-19 pandemic were retrospectively analyzed. By data analysis it was determined that the antibiogram has been done only in 21,84% of cases. In 72.25% of cases restricted antibiotic was included in therapy without prior antimicrobial therapy using unrestricted antibiotic. Monotherapy was included in 75,28% of cases, two antibiotics were used in 19,54% of cases, combination of three in 4,02% of cases, and there were 1,15% of cases of using 4 restricted antibiotics in therapy. Most commonly used antibiotics were meropenem (53 cases – 30,45%), amikacin (36 cases – 20,68%), vancomycin (33 cases – 18,7%). The combination of imipenem and cilastatin was used in 13 cases (7,47%). Most commonly isolated causative agents were Acinetobacter spp. (8), Pseudomonas aeruginosa (8), Staphylococcus aureus (6) and Clostridium difficile (4). Usage of restricted antibiotics has increased during COVID-19 (2021) – usage of amikacin has risen 1,5 times more than in 2019, ceftazidime 2,3 times, cefixime 1,6, meropenem 2,3, piperacillin/tazobactam 2,57 and vancomycin 1,63 times.The increase of restricted antibiotics’ usage during COVID-19  could highly negatively affect rational antibiotic use implementation, as well as the antimicrobial resistance.

Autori koji objavljuju u ovom časopisu pristaju na sledeće uslove:

  1. Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.
  2. Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.
  3. Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).